These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37806314)

  • 1. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Noureddin M; Khan S; Portell F; Jorkasky D; Dennis J; Khan O; Johansson L; Johansson E; Sanyal AJ
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1094-1105. PubMed ID: 37806314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
    Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
    Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
    Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
    Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
    Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Garvey WT; Frias JP; Jastreboff AM; le Roux CW; Sattar N; Aizenberg D; Mao H; Zhang S; Ahmad NN; Bunck MC; Benabbad I; Zhang XM;
    Lancet; 2023 Aug; 402(10402):613-626. PubMed ID: 37385275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
    Loomba R; Abdelmalek MF; Armstrong MJ; Jara M; Kjær MS; Krarup N; Lawitz E; Ratziu V; Sanyal AJ; Schattenberg JM; Newsome PN;
    Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):511-522. PubMed ID: 36934740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
    Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
    Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.